Drugs / INS068
Trials 6
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 13 trials | ||||||
| Phase 1 | NCT05887895 | May → Jul 2023 | diabetes mellitus | Jiangsu HengRui Medicine Co., Ltd. | Completed | No outcome recorded |
| Phase 1 | NCT05336071 | May 2022 | diabetes mellitus | Jiangsu HengRui Medicine Co., Ltd. | Completed | No outcome recorded |
| Phase 1 | NCT05031871 | Sep → Nov 2021 | type 2 diabetes mellitus | Jiangsu HengRui Medicine Co., Ltd. | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT04663282 | Feb 2021 → May 2022 | type 2 diabetes mellitus | Jiangsu HengRui Medicine Co., Ltd. | Completed | No outcome recorded |
| Phase 32 trials | ||||||
| Phase 3 | NCT05702073 | Mar 2023 → Jun 2024 | type 2 diabetes mellitus | Jiangsu HengRui Medicine Co., Ltd. | Completed | No outcome recorded |
| Phase 3 | NCT05699408 | Mar 2023 → Nov 2024 | type 2 diabetes mellitus | Jiangsu HengRui Medicine Co., Ltd. | Completed | No outcome recorded |
| Comparator or background therapy1 trial | ||||||
| Phase 2 | NCT05333835 Comparator | Jul 2022 → Mar 2024 | type 2 diabetes mellitus | Jiangsu HengRui Medicine Co., Ltd. | Unknown | No outcome recorded |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2025-09-30 | Jiangsu HengRui Medicine Co., Ltd. | Results 恒瑞医药新型长效胰岛素类似物舒地胰岛素（INS068）两项降糖III期研究亮相EASD简短口头报告 hengrui.com ↗
本研究达到预设的主要终点，治疗26周后，INS068组的HbA1c相对基线变化非劣于IGlar组。 |
All press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2025-09-30 | Jiangsu HengRui Medicine Co., Ltd. | 恒瑞医药新型长效胰岛素类似物舒地胰岛素（INS068）两项降糖III期研究亮相EASD简短口头报告 hengrui.com ↗ |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 8 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | INS068 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04663282 ↗ |
| Modality | Protein / enzyme biologic | “INS068 is a novel, soluble, and long-acting insulin analog.” PMID 38186641 ↗ Dec 2023 |
| Route | Subcutaneous | “INS068 injected subcutaneously once daily. Treat-to-target dose titration during the trial” NCT04663282 ↗ |